The analyst rating for WUXI BIO (02269.HK) was kept at "Overweight" by JPMorgan due to the company's pre-announced 2025 results exceeding market consensus and JPMorgan's expectations. The anticipated full-year revenue of RMB21.8 billion aligns with market consensus, while the expected net profit of RMB4.9 billion is approximately 11% higher than market consensus and 17% higher than JPMorgan's forecast. Additionally, JPMorgan raised its sales forecasts for 2025-2027 and projected strong sales growth for 2026 and 2027, which contributed to the decision to raise the target price from $37 to $51 and extend the target price deadline to December 2026.

BofA Securities

Neutral

maintain

$47

2026-02-12

Reason

BofA Securities

Price Target

$47

2026-02-12

maintain

Neutral

Reason

The analyst rating from BofA Securities for WUXI BIO is reiterated as Neutral due to the company's positive profit alert, which estimates a 16.7% year-over-year revenue growth to RMB21.8 billion for 2025. This performance aligns with the broker's expectations and is driven by a record number of new projects and expanded service offerings, particularly in the BsAb and ADC platforms. Additionally, the target price has been raised from HKD41.8 to HKD47, reflecting a positive outlook while maintaining a Neutral stance.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 02269

Unlock Now

02269 Should I Buy

02269 Should I Buy

Should You Buy WUXI BIO (02269) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

Growth

Profitability

Efficiency

People Also Watch